Burning Mouth Syndrome (BMS) is a chronic orofacial pain disorder characterized by burning sensations of the oral mucosa without evident causative lesions. Current treatment options often provide limited relief, highlighting the need for alternative therapeutic approaches. Recent evidence suggests that dysregulation of the endocannabinoid system plays a role in BMS patho- physiology, with altered expression of cannabinoid receptors in oral mucosa. We present a case of a 62-year-old postmenopausal female with a 3-year history of BMS refractory to conventional treatments including topical clonazepam, gabapentin, and alpha-lipoic acid. The patient was treated with CBD-dominant cannabis oil (20:1 CBD:THC ratio), starting at 5 mg CBD twice daily and titrated to 15mg CBD twice daily over 4 weeks. After 8 weeks of treatment, the patient reported a reduction in burning sensation from NRS 8/10 to 4/10, with concurrent improvement in xerostomia and taste alterations. Pain relief was maintained at 6-month follow-up with stable dosing and no significant adverse effects. This case suggests that CBD-dominant cannabis preparations may offer a promising therapeutic option for BMS through modulation of the endo- cannabinoid system.
Cite this paper
Gentili, L. , Scimia, P. , Nania, F. and Angeletti, C. (2025). Targeting the Endocannabinoid System in Burning Mouth Syndrome: A Case Report on CBD-Dominant Cannabis Oil. Open Access Library Journal, 12, e3432. doi: http://dx.doi.org/10.4236/oalib.1113432.
Pereira, S.R., Velasquez, J.T., Duggan, S., Ivanisevic, B., McKenna, J.P., McCreary, C., et al. (2020) Recent Advances in the Understanding of the Aetiology and Therapeutic Strategies in Burning Mouth Syndrome: Focus on the Actions of Cannabinoids. European Journal of Neuroscience, 55, 1032-1050. https://doi.org/10.1111/ejn.14712
Imamura, Y., Shinozaki, T., Okada‐Ogawa, A., Noma, N., Shinoda, M., Iwata, K., et al. (2019) An Updated Review on Pathophysiology and Management of Burning Mouth Syndrome with Endocrinological, Psychological and Neuropathic Perspectives. Journal of Oral Rehabilitation, 46, 574-587. https://doi.org/10.1111/joor.12795
Borsani, E., Majorana, A., Cocchi, M.A., Conti, G., Bonadeo, S., Padovani, A., et al. (2014) Epithelial Expression of Vanilloid and Cannabinoid Receptors: A Potential Role in Burning Mouth Syndrome Patho-genesis. Histology and Histopathology, 29, 523-533.
Beneng, K., Yilmaz, Z., Yiangou, Y., McParland, H., Anand, P. and Ren-ton, T. (2010) Sensory Purinergic Receptor P2X3 Is Elevated in Burning Mouth Syndrome. International Journal of Oral and Maxillofacial Surgery, 39, 815-819. https://doi.org/10.1016/j.ijom.2010.03.013
Gambino, A., Cabras, M., Panagio-takos, E., Calvo, F., Macciotta, A., Cafaro, A., et al. (2020) Evaluating the Suitability and Potential Efficiency of cannabis Sa-tiva Oil for Patients with Primary Burning Mouth Syndrome: A Prospective, Open-Label, Single-Arm Pilot Study. Pain Medi-cine, 22, 142-151. https://doi.org/10.1093/pm/pnaa318
Liu, Y., Kim, Y., Yoo, T., Han, P. and Inman, J. (2017) Burning Mouth Syndrome: A Systematic Review of Treatments. Oral Diseases, 24, 325-334. https://doi.org/10.1111/odi.12660
Marzo, V.D., Bifulco, M. and Petrocellis, L.D. (2004) The Endocannabinoid Sys-tem and Its Therapeutic Exploitation. Nature Reviews Drug Discovery, 3, 771-784. https://doi.org/10.1038/nrd1495
Mücke, M., Phillips, T., Radbruch, L., Petzke, F. and Häuser, W. (2018) Canna-bis-based Medicines for Chronic Neuropathic Pain in Adults. Cochrane Database of Systematic Reviews, No. 3, CD012182. https://doi.org/10.1002/14651858.cd012182.pub2
Russo, E. (2008) Cannabinoids in the Management of Difficult to Treat Pain. Therapeutics and Clinical Risk Management, 4, 245-259. https://doi.org/10.2147/tcrm.s1928
Häuser, W., Finn, D.P., Kalso, E., Krcevski‐Skvarc, N., Kress, H., Morlion, B., et al. (2018) European Pain Federation (EFIC) Position Paper on Appropriate Use of Cannabis‐Based Medicines and Medical Cannabis for Chronic Pain Management. European Journal of Pain, 22, 1547-1564. https://doi.org/10.1002/ejp.1297